Podcast: How Imagion is bringing cancer diagnostics into the 21st century.
“According to Imagion Biosystems (ASX:IBX) CEO, Robert Proulx, advancements in imaging have been slow, with no real progress made for half a century. Imagion is looking to redress that balance and speaks with Finfeed about the cancer diagnostics market, how Imagion is leading the way in bringing the field into the 21st century and why people should seek out early detection, if the feel vulnerable to cancer in any way.”
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited